

### **DARPA** Next-Generation Non-Surgical Neurotechnology (N<sup>3</sup>)

# N<sup>3</sup> Proposer's Day

Dr. Al Emondi



### Next generation approach to brain interfaces



#### DOD Problem: Able-bodied military personnel cannot use current neural interfaces



### Goal: Create reliable neural interfaces without the need for surgery or implanted electrodes

Facilitate multitasking at the speed of thought

Interface with smart decision aids



# **DARPA** Two Technical Areas



	TA1: Noninvasive		TA2: Minutely Invasive
Invasiveness	External device	>	Injectable/ingestible/intranasal
Example Technology	Ultrasound, light, RF, magnetic fields		Nanotechnology, membrane modifications, molecular assembly
Signal Quality	Neural ensemble activity		Single neuron activity
5	stimulator sensor		stimulator sensor



### **TA1: Completely Noninvasive Neural Interfaces**



#### **Objective**: Create a noninvasive read/write system

PHASE I Develop subcomponent technology

Develop systems level design link margin power budgets, channelization approaches

**Fabricate subcomponents** circuits, sensor, emitter, hardware

Characterize subcomponents resolution and latency performance

Assess scattering and attenuation compare to systems level design parameters

Demonstrate read and write through "skull and tissue like" mediums

Bench top demo

PHASE II Integrate and validate in vivo

Integrate subcomponents combine multiple read and write subcomponents into one device

Evaluate physical properties crosstalk, SNR, and safety parameters of integrated device *in vivo* 

Develop algorithms decode neural ensemble activity and encode sensory feedback to the brain



In vivo proof of concept

PHASE III Refine and demonstrate

**Characterize refined system** meet metrics for bidirectional system

Refine algorithms achieve lower system latency

#### Demonstrate system capabilities

decode motor and cognitive signals, and encode sensory feedback

#### Design DoD relevant final demo

ex. simultaneously perform multiple tasks



In field proof of concept

Deliverable: Human demonstration of closed loop prototype system in a DoD relevant task



# **TA1: Noninvasive metrics**



#### Phase I

Read and Write Subcomponents

Spatial resolution <1 mm<sup>3</sup>

Temporal resolution <10 ms

**Stability** continuous operation for  $\ge 2$  hrs

Accuracy (read/write) correlation to ground truth accuracy ≥ 95% Phase II

**Integrated Device** 

Safety ≤ 1°C rise in tissue volume being read from/written to

> Closed loop system latency < 100 ms

> > Control signals ≥ 3 DOF

Sensory signals ≥ 3 categories (ex: detection, alarm)

Integrated device size ≤ 125 cm<sup>3</sup>

Channel count read channels/volume (≥16/16mm<sup>3</sup>) write channels/volume (≥16/16mm<sup>3</sup>) Phase III

**Final System** 

Closed loop system latency < 50 ms

> Control signals ≥ 6 DOF

Sensory signals ≥ 6 categories

Multifocal capability ≥ 4 read/write locations without crosstalk



### **TA2: Minutely Invasive Neural Interfaces**



#### **Objective:** Create a minutely invasive read/write system

**PHASE I** Develop subcomponents and nanotransducers

Develop system level design nanotransducer and sensor/stimulator

Fabricate subcomponents circuits, hardware and nanotransducer (particle, genetic component, encapsulation material)

**Characterize nanotransducer** cell type specificity at single neuron resolution

 $\begin{array}{c} \textbf{Demonstrate system interaction}\\ sensor/stimulator \leftrightarrow nanotransducer \end{array}$ 

In vitro demo

**PHASE II** Integrate and validate *in vivo* 

Integrate subcomponents combine multiple read and write subcomponents into one device

**Evaluate physical properties** crosstalk, SNR, specificity of sensor/stimulator toxicity and stability of nanotransducer

Develop algorithms decode and encode from/to single neurons

Identify patient population prepare for clinical proof of concept

**Optimize peripheral delivery route** cross the BBB targeting specific neurons

Preclinical proof of concept

PHASE III Refine and demonstrate

Characterize refined system bidirectional system and interaction with nanotransducer

> Refine algorithms achieve lower system latency

Demonstrate system capabilities decode motor and cognitive signals, and encode sensory feedback

Design DoD relevant final demo in a patient population

Ş

Clinical proof of concept

Deliverable: High spatiotemporal resolution bidirectional system demonstrated in animal and human.



# **TA2: Minutely Invasive Metrics**



#### Phase I

Subcomponents and Transducers

Spatial resolution  $<50 \ \mu m^3$ 

Temporal resolution <10 ms

**Stability** Continuous operation for  $\ge 2$  hrs

Accuracy (read/write) Correlation to ground truth accuracy ≥ 95%

**Cell type specificity** Excitatory/inhibitory control for stimulation

> **Delivery** Viable strategy identified

Phase II

Integrated Device

Safety ≤ 1°C rise in tissue volume being read from/written to

> Closed loop system latency < 100 ms

> > Control signals ≥ 5 DOF

Sensory signals ≥ 5 categories (ex: detection, alarm)

Integrated device size ≤ 125 cm<sup>3</sup>

Channel count read channels/volume (≥16/16mm<sup>3</sup>) write channels/volume (≥16/16mm<sup>3</sup>)

#### Phase III

**Final System** 

Closed loop system latency < 50 ms

> Control signals ≥ 10 DOF

Sensory signals ≥ 10 categories

Multifocal capability ≥ 4 read/write locations without crosstalk



## N<sup>3</sup> Notional System







### N<sup>3</sup> program structure and milestones





#### **FDA** milestones

21 Mo. Pre-IDE submission for TA1

**24 Mo**. Pre-IDE/IND submission for TA2

27 Mo. IDE submission for TA1

**30 Mo**. IDE/IND submission for TA2

demos

independent read and write capabilities

humans) open loop read and write capabilities

(animals, humans) closedloop of integrated read and write capabilities

48 Mo. Demo: DoD relevant task with closedloop control and feedback in humans





- 1. Fabrication description for subcomponents (TA1 and TA2) and nanotransducer (TA2)
  - Provide a detailed development timeline that describes relevant microfabrication or nanofabrication processes

#### 2. System-level design descriptions

- Describe the components, and a strategy for identifying system parameters
- Describe the underlying physics, how to overcome scattering/attenuation challenges

#### 3. Phase I, II, III demonstration descriptions

Describe demonstration ideas, justify the chosen method and why it is DoD relevant

#### 4. System integration description

Identify a system integrator, and describe how to integrate read/write subcomponents

#### 5. Safety and histology description

Describe procedures to collect the appropriate safety and histology data for FDA approval and to meet N<sup>3</sup> metrics

#### 6. Security Measures

Describe approaches to ensure confidentiality, integrity, and availability to prevent spoofing, tampering, or denial of system

#### 7. Ethical, Legal, and Societal Implications (ELSI)

Address the potential ELSI implications of the proposed technology





### To fully address the BAA you will likely need to team with other entities

- You must find your collaborators on your own
- > Your team should submit a unified proposal under a single PI
- > This BAA is open to educational institutions, government labs, and/or private companies
- Foreign entities may join a team or submit as the PI
- If you are a member of a team, you may join any number of other teams or form your own and submit a proposal as PI
- Note that the cost volume for each team member must be at the same level of details as for the PI



# **Additional Advice**



- Read the BAA and follow all instructions carefully
- A successful proposal addresses all aspects of the BAA
- Pay attention to "must" and "should" language in the BAA
- > Do not submit work that is not applicable to the BAA
- Do not propose to do anything that is not directly relevant to the BAA
- > Do not propose incremental improvements to existing technology
- > Do not submit an irrelevant or incomplete proposal in the hope we'll fund it anyway
- Submitting a proposal abstract is **highly recommended**





# Teaming is very important! Use today to network and team

Approved for Public Release, Distribution Unlimited